Biotherapeutics

#Biopharmaceuticals #Biotherapeutics #Clinical trials

4D Pharma announces positive topline results for the treatment of asthma 

4D Pharma has announced positive topline results from Part A of its Phase I/II clinical trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.  Part A  The Phase I/II trial is a multi-center, double-blind, placebo-controlled study in patients… Read More

#News

#Biotherapeutics #Covid-19

Pharmacokinetic study for developing kidney disease and injury therapies 

XORTX Therapeutics has chosen Altasciences to conduct a pharmacokinetic bridging study in support of the XRx-008 programme for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with Covid-19.   Context   XORTX’s formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order… Read More

#News

#Biotherapeutics #Cell therapy #Gene editing #Immunotherapy #T-Cells

Atara Biotherapeutics’ plans to tackle MS with Epstein-Barr Virus

Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biotechnology #Biotherapeutics #Clinical trials #Funding

Northwest Biotherapeutics announces $15 million financing    

Northwest Biotherapeutics, a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers in the United States, has announced the closing of a $15 million financing.  The company plans to use the funding to help accelerate its activities related to its brain cancer programme.    The financing is in the form… Read More

#News

#Antibodies #Biotherapeutics #Covid-19 #Data #Funding #Immunology / Virology & Vaccines

Twist Bioscience spins out Covid antibodies into Revelar Biotherapeutics

Twist Bioscience has launched Revelar Biotherapeutics to develop and commercialise an antibody that neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies.   In addition, Revelar will have the ability to leverage the antibody discovery and optimisation platform of Twist Biopharma to license additional antibodies for up to five targets over the next four… Read More

#Covid-19 #News

#Assays #Biotherapeutics #Drug targets #Mass spectrometry / NMR #Webinar

The challenges of peptide and protein quantification: Webinar

The importance of biotherapeutics as a class of drugs continues to increase. Indeed, their low toxicity and high specificity justify their investigation as drug candidates. Yet, quantification studies of biotherapies in complex biological matrices can be very challenging. In particular, high background noise and interferences due to endogenous proteins… Read More

#News

#Antivirals #Biotherapeutics #Covid-19 #Immunology / Virology & Vaccines

Beximco Pharma introduces an oral antiviral drug for Covid-19 treatment 

Beximco Pharmaceuticals has launched a generic molnupiravir, an oral antiviral drug for symptomatic Covid-19 patients developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics, following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh.   Molnupiravir is world’s first oral product to treat symptomatic Covid-19,… Read More

#Covid-19 #News #Trending News

#Assays #Biotherapeutics #Drug targets #Mass spectrometry / NMR #Webinar

Webinar: How to tackle the challenges of peptide and protein quantification

The importance of biotherapeutics as a class of drugs continues to increase. Indeed, their low toxicity and high specificity justify their investigation as drug candidates. Yet, quantification studies of biotherapies in complex biological matrices can be very challenging. In particular, high background noise and interferences due to endogenous proteins… Read More

#News

#Biotherapeutics #Clinical trial #Covid-19 #FDA

UK becomes first country to approve a Covid-19 antiviral pill 

The MHRA has authorised Merck and Ridgeback Biotherapeutics’ molnupiravir pill for the treatment of at-risk Covid-19 patients, following positive clinical trial results. Molnupiravir is the first oral antiviral medicine authorised for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk… Read More

#News

#Antibodies #Biotherapeutics #Therapeutics

New platform could improve potency and efficacy of therapeutic antibodies 

PerkinElmer is expanding its Horizon Discovery CHOSOURCE platform to include a new expression cell line, CHO-K1 ADCC+, which may improve potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics, as well as reduce dosage requirements and side effects for patients.   This new expression host was built… Read More

#News

#Biotherapeutics #Gene therapy #Global data

Gene therapies could revolutionise CVDs, data says 

Gene therapies could revolutionise the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The data and analytics company notes that there are currently 87* CVD gene therapies currently in development, and they hold potential to vastly improve patients’ quality of life.  Fiona Chisholm, Pharma Analyst at GlobalData said: “As… Read More

#Market Reports #News #Trends & Analysis

#Antibodies #Biotherapeutics #Collaboration #Drug discovery

Collaboration to support preclinical drug discovery research 

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that… Read More

#Business & Investment #News

#Biotherapeutics #Collaboration #Funding #HIV #Pharma

This week in drug discovery (16-20 August) 

News round-up by DDW’s Megan Thomas for 16-20 August  DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research.   1. OGT training initiative with CytoCell University … Read More

#News #Trending News

#Biomanufacturing #Biosciences #Biotherapeutics #Drug development #Therapeutics

Partnership to develop and manufacture biosimilars

Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture. The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy,… Read More

#News

#Biotherapeutics #Clinical trial #mRNA #Therapeutics

Positive interim results from Phase I study for sickle cell disease treatment

Massachusetts-headquartered Fulcrum Therapeutics has announced positive interim results from the ongoing single and multiple-ascending dose (SAD and MAD) Phase I trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent and selective small molecule inhibitor of EED designed to increase the expression of fetal hemoglobin (HbF) with the… Read More

#News #Trending News

#Assays #Biotherapeutics #C elegans #Drug development #Drug discovery #Therapeutics #Viosciences

Unlocking the microbiome as a target for drug discovery using C. elegans

David Weinkove, CEO Magnitude Biosciences, examines the untapped microbiome and its potential into helping unlock new therapies. Why the microbiome? The human microbiome is an important emerging field for drug discovery that harbours an array of life-changing medicines for patients. Whilst it is increasingly acknowledged that the human microbiome holds… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News